Chronic Myocardial Ischemia With Refractory Angina
BCDABioCardiaCatalyst overview
Research summary
This catalyst tracks a Phase 2 update for CardiAMP Autologous Cell Therapy (BCDA-02) (Cell Therapy) in Chronic Myocardial Ischemia With Refractory Angina. The expected timing is based on the latest available company guidance and may change.
05/15/26:- EuroPCR oral presentation accepted for May 20, 2026. 05/21/26:- EuroPCR presented open-label cohort results; 2-year follow-up showed better exercise tolerance and fewer angina episodes. 08/12/26:- EuroPCR cohort results were reiterated, including durable exercise tolerance and fewer angina episodes through two years.
Verification
Confirm timing and program details against the company announcement or filing.